IL-1-induced Inflammation Promotes Development of Leishmaniasis in Susceptible BALB/c Mice
Overview
Authors
Affiliations
The role of host-derived IL-1 on the course of Leishmania major infection in susceptible BALB/c mice was assessed. Manifestations of the disease were more severe in mice deficient in the physiological inhibitor of IL-1, the IL-1 receptor antagonist (IL-1Ra) in comparison with control mice. In mice lacking one of the IL-1 genes (IL-1alpha or IL-1beta), there was delayed development of the disease and more attenuated systemic inflammatory responses. IL-1alpha-deficient mice were slightly more resistant to L. major infection compared with IL-1beta-knockout mice. During disease progression in IL-1Ra KO and control mice, myeloid-derived suppressor cells invaded the spleen, concomitant to suppression of T cell-mediated immunity and expression of systemic high levels of pro-inflammatory cytokines. In IL-1-deficient mice, T(h)1 responses were still apparent, even at late stages of the disease. Thus, dose-dependent effects of IL-1 were shown to influence the pathogenesis of murine leishamaniasis in susceptible BALB/c mice. Physiological and supra-physiological levels of IL-1 in the microenvironment promoted an exacerbated form of disease, whereas sub-physiological doses of IL-1 induced a less progressive disease. Thus, manipulation of IL-1 levels in the host, using the IL-1Ra or specific antibodies, has the potential to alleviate symptoms of visceral manifestations of leishmaniasis.
Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis.
Lafleur A, Daffis S, Mowbray C, Arana B Vaccines (Basel). 2024; 12(10).
PMID: 39460345 PMC: 11511131. DOI: 10.3390/vaccines12101179.
Borba P, Lago J, Lago T, Araujo-Pereira M, Queiroz A, Barud H Pathogens. 2024; 13(5).
PMID: 38787268 PMC: 11124396. DOI: 10.3390/pathogens13050416.
Molecular regulation of NLRP3 inflammasome activation during parasitic infection.
Alonaizan R Biosci Rep. 2024; 44(5).
PMID: 38623843 PMC: 11096646. DOI: 10.1042/BSR20231918.
Farias Amorim C, Lovins V, Singh T, Novais F, Harris J, Lago A Sci Transl Med. 2023; 15(718):eadh1469.
PMID: 37851822 PMC: 10627035. DOI: 10.1126/scitranslmed.adh1469.
Khandibharad S, Nimsarkar P, Singh S Curr Res Immunol. 2022; 3:186-198.
PMID: 36051499 PMC: 9424266. DOI: 10.1016/j.crimmu.2022.08.007.